Condition: Primary Membranous Nephropathy · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Loma Linda, California, United States | Recruiting |
| Research Site | San Diego, California, United States | Recruiting |
| Research Site | Minneapolis, Minnesota, United States | Recruiting |
| Research Site | Rochester, Minnesota, United States | Recruiting |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | Buenos Aires, Argentina | Recruiting |
| Research Site | CABA, Argentina | Recruiting |
| Research Site | Ciudad de Buenos Aires, Argentina | Recruiting |
| Research Site | La Plata, Argentina | Not Yet Recruiting |
| Research Site | Rosario, Argentina | Recruiting |
| Research Site | Santa Fe, Argentina | Withdrawn |
| Research Site | Santa Fe, Argentina | Withdrawn |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07157787